Allergan Reports the Acceptance of EMA's MAA for Abicipar to Treat Neovascular Age-Related Macular Degeneration
Shots:
- Molecular Partners announces that EMA has validated the MAA of its partner Allergan for Abicipar to treat patients with nAMD
- Post-approval- Abicipar will be the first anti-VEGF therapy to maintain vision gains with a 12-week dosing interval. The companies collaborated to advance clinical programs in ophthalmology and to robust pipeline of DARPin drug candidates in oncology and immuno-oncology
- Abicipar pegol is an anti-VEGF therapy based on the Molecular Partners’ DARPin platform and currently being evaluated in P-III study. Additionally- Molecular Partners has terminated its agreement with Amgen for exclusive development & commercialization of MP0310 which is expected to enter into the clinic in H2’19
Click here to read full press release/ article | Ref: Molecular Partners | Image: Stat News
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
